¥¤¥Ù¥ë¥á¥¯¥Á¥ó
¥¤¥Ù¥ë¥á¥¯¥Á¥ó½ªÎ»¤Î¤ªÃΤ餻
- ¥¤¥Ù¥ë¥á¥¯¥Á¥ó ¿··¿¥³¥í¥Ê´µ¼Ô¤ËÅêÍ¿¤â¸ú²Ì¤ß¤é¤ì¤º ËÌΤÂç¡¡2023ǯ5·î24Æü 23»þ47ʬ¡¢NHK
´óÀ¸Ã¸¶°ø¤Ç¼ºÌÀ¤Ê¤É¤¬°ú¤µ¯¤³¤µ¤ì¤ë´¶À÷¾É¤ÎÆÃ¸úÌô¡Ö¥¤¥Ù¥ë¥á¥¯¥Á¥ó¡×¤Ë¤Ä¤¤¤Æ¡¢¿··¿¥³¥í¥Ê´µ¼Ô¤ËÅêÍ¿¤·¤Æ¤â¸ú²Ì¤¬¤ß¤é¤ì¤Ê¤«¤Ã¤¿¤È¤¹¤ë·ë²Ì¤ò¡¢¼£¸³¤ò¿Ê¤á¤Æ¤¤¤¿ËÌΤÂç³ØÉ±¡¤Ê¤É¤Î¥°¥ë¡¼¥×¤¬È¯É½¤·¤Þ¤·¤¿¡£
¡¡
¼£¸³¤ÏËÌΤÂç³ØÉ±¡¤Ê¤É¤Î¥°¥ë¡¼¥×¤¬¹Ô¤¤¡¢º£·î22Æü¡¢³¤³°¤Î°å³Ø»¨»ï¤Ë·ë²Ì¤ò¤Þ¤È¤á¤¿ÏÀʸ¤òȯɽ¤·¤Þ¤·¤¿¡£
¡¡
¤½¤ì¤Ë¤è¤ê¤Þ¤¹¤È¡¢¼£¸³¤Ï2020ǯ8·î¤«¤é¤ª¤È¤È¤·10·î¤Þ¤Ç¿··¿¥³¥í¥Ê¤Ë´¶À÷¤·¤¿20ºÐ°Ê¾å¤ÎÃæÅù¾É¤Þ¤Ç¤Î´µ¼Ô248¿Í¤òÂоݤ˹Ԥï¤ì¡¢¥¤¥Ù¥ë¥á¥¯¥Á¥ó¤ò1²óÉþÍѤ¹¤ë¥°¥ë¡¼¥×¤Èµ¶¤ÎÌô¤òÉþÍѤ¹¤ë¥°¥ë¡¼¥×¤Ëʬ¤±¤Æ¡¢´µ¼Ô¤â°å»Õ¤â¤É¤Á¤é¤¬ÅêÍ¿¤µ¤ì¤Æ¤¤¤ë¤«Ê¬¤«¤é¤Ê¤¤ÊýË¡¤ÇPCR¸¡ºº¤Ç±¢À¤È¤Ê¤ë¤Þ¤Ç¤Î´ü´Ö¤òÈæ³Ó¤·¤Þ¤·¤¿¡£
¡¡
¤½¤Î·ë²Ì¡¢¤¤¤º¤ì¤Î¥°¥ë¡¼¥×¤Ç¤â14ÆüÁ°¸å¤Ç±¢À¤È¤Ê¤ê¡¢±¢À¤È¤Ê¤ë¤Þ¤Ç¤Î»þ´Ö¤Ëº¹¤Ï¤Ê¤¯¡¢¥¤¥Ù¥ë¥á¥¯¥Á¥ó¤ÎÅêÍ¿¤Ç»þ´Ö¤òû½Ì¤¹¤ë¸ú²Ì¤Ï¤Ê¤«¤Ã¤¿¤È·ëÏÀ¤Å¤±¤Æ¤¤¤Þ¤¹¡£
- Efficacy and safety of single-dose ivermectin in mild-to-moderate COVID-19: the double-blind, randomized, placebo-controlled CORVETTE-01 trial¡¡Tatsuhiko Wada, et al., Front. Med., 22 May 2023, Sec. Infectious Diseases: Pathogenesis and Therapy, Volume 10 (2023) 10.3389/fmed.2023.1139046
- ¶½Ï¡¡¿··¿¥³¥í¥Ê¥¦¥¤¥ë¥¹´¶À÷¾É´µ¼Ô¤òÂоݤȤ·¤¿¡ÖK-237¡×¡Ê¥¤¥Ù¥ë¥á¥¯¥Á¥ó¡Ë¤ÎÂè·ÁêÎ×¾²»î¸³·ë²Ì¤Ë´Ø¤¹¤ë¤ªÃΤ餻¡¡2022.09.26¥×¥ì¥¹¥ê¥ê¡¼¥¹¡¢¶½Ï³ô¼°²ñ¼Ò
Ëܻ¤Ï¡¢·Ú¾É¤Î¿··¿¥³¥í¥Ê¥¦¥¤¥ë¥¹´¶À÷¾É¡ÊCOVID-19¡Ë´µ¼Ô1,030Îã¤òÂоݤȤ·¤Æ¼Â»Ü¤·¤¿¹ñºÝ¶¦Æ±¡¢Â¿»ÜÀß¶¦Æ±¡¢¥×¥é¥»¥ÜÂоȡ¢Ìµºî°Ù²½¡¢Æó½ÅÌÕ¸¡¡¢Ê¹Է²´ÖÈæ³Ó»î¸³¤Ç¤¹¡£Ëܺޤϡ¢¼çÍ×ɾ²Á¹àÌܤǤ¢¤ë¼£¸³Ìô¤ÎÅêÍ¿³«»Ï¤«¤é168»þ´Ö¤Þ¤Ç¤ÎÎ×¾²¾É¾õ¤¬²þÁ±·¹¸þ¤Ë»ê¤ë¤Þ¤Ç¤Î»þ´Ö¤ò¥×¥é¥»¥Ü¤ÈÈæ³Ó¤·¤¿·ë²Ì¡¢°ÂÁ´À¤Ï³Îǧ¤µ¤ì¤Þ¤·¤¿¡£¤Þ¤¿¡¢»àË´Îã¤Ï¤Ê¤¯¡¢½Å¾É²½Îã¤â¤Û¤È¤ó¤Éǧ¤á¤é¤ì¤Þ¤»¤ó¤Ç¤·¤¿¡£¤·¤«¤·¤Ê¤¬¤é¡¢¥ª¥ß¥¯¥í¥ó³ô¤¬¼çή¤È¹Í¤¨¤é¤ì¤ëº£²ó¤ÎÂоݴµ¼Ô¤Ë¤ª¤¤¤Æ¤Ï¡¢Ëܺޤª¤è¤Ó¥×¥é¥»¥Ü¤È¤â¤ËÅêÍ¿³«»Ï4ÆüÁ°¸å¤Ç¾É¾õ¤Î·Ú¾É²½¤¬Ç§¤á¤é¤ì¤Þ¤·¤¿¤¬¡¢ËܺޤÎ͸úÀ¤ò¸«½Ð¤¹¤³¤È¤¬¤Ç¤¤Þ¤»¤ó¤Ç¤·¤¿¡£¶½Ï¤ϰú¤Â³¤¡¢ºÙÉô¤ËÅϤêÍÍ¡¹¤Ê³ÑÅÙ¤«¤éËܻ·ë²Ì¤Î¥Ç¡¼¥¿²òÀϤò¿Ê¤á¡¢ËܺޤβÄǽÀ¤Ë¤Ä¤¤¤Æ¤µ¤é¤Ë³Îǧ¤·¤Æ¤Þ¤¤¤ê¤Þ¤¹¡£¤Ê¤ª¡¢Ëܻ·ë²Ì¤Î¾ÜºÙ¤Ë¤Ä¤¤Þ¤·¤Æ¤Ï¡¢³Ø²ñ¤Þ¤¿¤ÏÏÀʸ¤Ë¤Æ¸øÉ½¤¹¤ëͽÄê¤Ç¤´¤¶¤¤¤Þ¤¹¡£
- ¥¤¥Ù¥ë¥á¥¯¥Á¥ó ¥³¥í¥Ê¼£ÎÅÌô¤Î¾µÇ§¿½ÀÁ¤òÃÇǰ ͸úÀ¸«¤é¤ì¤º¡¡2022ǯ9·î26Æü 19»þ15ʬ¡¢NHK
¼£¸³¤Ïµîǯ11·î¤«¤éÀè·î¤Þ¤Ç12ºÐ°Ê¾å¤Î·Ú¾É¤Î¥³¥í¥Ê´µ¼Ô1030¿Í¤òÂоݤ˹Ԥï¤ì¡¢°ìÆü1²ó¡¢3Æü´Ö¡¢¥¤¥Ù¥ë¥á¥¯¥Á¥ó¤òÉþÍѤ¹¤ë¥°¥ë¡¼¥×¤Èµ¶¤ÎÌô¤òÉþÍѤ¹¤ë¥°¥ë¡¼¥×¤Ëʬ¤±¤Æ¡¢´µ¼Ô¤â°å»Õ¤â¤É¤Á¤é¤¬ÅêÍ¿¤µ¤ì¤Æ¤¤¤ë¤«Ê¬¤«¤é¤Ê¤¤ÊýË¡¤ÇÈæ³Ó¤·¤¿¤È¤¤¤¦¤³¤È¤Ç¤¹¡£
¡¡
¤½¤Î·ë²Ì¡¢¤¤¤º¤ì¤Î¥°¥ë¡¼¥×¤Ç¤âÅêÍ¿¤«¤é4ÆüÁ°¸å¤ÇȯǮ¤ä¤Î¤É¤ÎÄˤߤʤɤξɾõ¤¬¼£¤Þ¤ê¡¢Ìô¤Ë¤è¤Ã¤Æ²þÁ±¤·¤¿¤È¤¤¤¦Í¸úÀ¤¬¸«¤¤¤À¤»¤Ê¤«¤Ã¤¿¤È¤¤¤¦¤³¤È¤Ç¡¢²ñ¼Ò¤Ï¿··¿¥³¥í¥Ê¤Î¼£ÎÅÌô¤È¤·¤Æ¤Î¾µÇ§¿½ÀÁ¤òÃÇǰ¤¹¤ë¤Èȯɽ¤·¤Þ¤·¤¿¡£
¡¡
¥¤¥Ù¥ë¥á¥¯¥Á¥ó¤Ï¡¢¥Î¡¼¥Ù¥ëÀ¸Íý³Ø¡¦°å³Ø¾Þ¤ò¼õ¾Þ¤·¤¿ËÌΤÂç³Ø¤ÎÂç¼ÃÒÆÃÊ̱ÉÍÀ¶µ¼ø¤Î¸¦µæ¤ò¸µ¤Ë³«È¯¤µ¤ì¤¿¡¢´óÀ¸Ãî¤Ë¤è¤Ã¤Æ¼ºÌÀ¤ä¥ê¥ó¥Ñ´É¤Î¼ð¤ì¤¬°ú¤µ¯¤³¤µ¤ì¤ëɵ¤¤ÎÆÃ¸úÌô¤Ç¡¢¿··¿¥³¥í¥Ê¤Ø¤Î¸ú²Ì¤¬¤¢¤ë¤«³Æ¹ñ¤Ç¸¦µæ¤¬¿Ê¤á¤é¤ì¤Þ¤·¤¿¤¬¡¢¤³¤È¤·3·î¡¢¥Ö¥é¥¸¥ë¤Ê¤É¤Î¸¦µæ¥°¥ë¡¼¥×¤¬Æþ±¡¤Ë»ê¤ë¥ê¥¹¥¯¤ò²¼¤²¤ë¤Ê¤É¤Î¸ú²Ì¤Ï¤Ê¤«¤Ã¤¿¤È¤¹¤ëÎ×¾²»î¸³¤Î·ë²Ì¤òȯɽ¤·¤Æ¤¤¤Þ¤·¤¿¡£
¡¡
»°ÎØË§¹°¼ÒĹ¤Ï¡ÖÁ´¼Òµó¤²¤Æ¼£¸³¤ËÎפó¤Ç¤¤¿¤¬¡¢¤³¤Î·ë²Ì¤Ç¤Ï¾µÇ§¿½ÀÁ¤ò¹Í¤¨¤ë¤³¤È¤Ï¤Ç¤¤Ê¤¤¡£·ë²Ì¤ò¼õ¤±Æþ¤ì¤¿¤¤¡×¤È½Ò¤Ù¤Þ¤·¤¿¡£
ÏÀʸ´ØÏ¢
¥¤¥Ù¥ë¥á¥¯¥Á¥óÎ×¾²»î¸³ ¿··¿¥³¥í¥Ê¤ÎÆþ±¡Í½Ëɸú²Ìǧ¤á¤é¤ì¤º¡¡
2022ǯ3·î31Æü 16»þ42ʬ¡¢NHK
Î×¾²»î¸³¤Î·ë²Ì¤Ï¡¢¥Ö¥é¥¸¥ë¤ÎÊ£¿ô¤ÎÂç³Ø¤Ê¤É¤Î¸¦µæ¥°¥ë¡¼¥×¤¬¡¢¹ñºÝŪ¤Ê°å³Ø»¨»ï¡Ö¥Ë¥å¡¼¡¦¥¤¥ó¥°¥é¥ó¥É¡¦¥¸¥ã¡¼¥Ê¥ë¡¦¥ª¥Ö¡¦¥á¥Ç¥£¥·¥ó¡×¤Ëȯɽ¤·¤Þ¤·¤¿¡£
¸¦µæ¥°¥ë¡¼¥×¤Ï¡¢µîǯ3·î¤«¤é8·î¤Ë¤«¤±¤Æ¡¢ÈîËþ¤äÅüǢɡ¢¹â·ì°µ¤Ê¤É¡¢¿··¿¥³¥í¥Ê¤Î½Å¾É²½¥ê¥¹¥¯¤¬¤¢¤ë18ºÐ°Ê¾å¤Î´µ¼Ô1358¿Í¤Ë¤Ä¤¤¤Æ¡¢È¯¾É¤«¤é7Æü°ÊÆâ¤Ë¡Ö¥¤¥Ù¥ë¥á¥¯¥Á¥ó¡×¤ò°ìÆü¤Ë1²ó¡¢3Æü´Ö¡¢ÉþÍѤ¹¤ë¥°¥ë¡¼¥×¤Èµ¶¤ÎÌô¤òÉþÍѤ¹¤ë¥°¥ë¡¼¥×¤Ëʬ¤±¤Æ·Ð²á¤òÄ´¤Ù¤Þ¤·¤¿¡£
¤½¤Î·ë²Ì¡¢4½µ´Ö°ÊÆâ¤ËÆþ±¡¤¹¤ë¤«µßµÞ³°Íè¤ò¼õ¿Ç¤·¤¿´µ¼Ô¤Ï¡Ö¥¤¥Ù¥ë¥á¥¯¥Á¥ó¡×¤òÉþÍѤ·¤¿¥°¥ë¡¼¥×¤Ç14.7¡ó¡¢µ¶¤ÎÌô¤Î¥°¥ë¡¼¥×¤Ç¤Ï16.3¡ó¤Ç¡¢Åý·×³ØÅª¤ËͰդʺ¹¤Ï¸«¤é¤ì¤Ê¤«¤Ã¤¿¤È¤¤¤¦¤³¤È¤Ç¤¹¡£
¤Þ¤¿¡¢È¯¾É¤«¤é7ÆüÌܤǤÎÂÎÆâ¤Î¥¦¥¤¥ë¥¹Î̤θº¾¯¤ä²óÉü¤¹¤ë¤Þ¤Ç¤Î´ü´Ö¡¢¤½¤ì¤Ë»àË´¤¹¤ë¥ê¥¹¥¯¤Ë¤Ä¤¤¤Æ¤âº¹¤Ï¸«¤é¤ì¤Ê¤«¤Ã¤¿¤È¤·¤Æ¤¤¤Þ¤¹¡£
- Effect of Early Treatment with Ivermectin among Patients with Covid-19¡¡Gilmar Reis, Eduardo A.S.M. Silva, Daniela C.M. Silva, Lehana Thabane, Aline C. Milagres, Thiago S. Ferreira, Castilho V.Q. dos Santos, Vitoria H.S. Campos, Ana M.R. Nogueira, Ana P.F.G. de Almeida, Eduardo D. Callegari, Adhemar D.F. Neto, et al., The new england journal of medicine
¥¤¥Ù¥ë¥á¥¯¥Á¥ó¡¢RCT¤Ç͸úÀ¼¨¤»¤º¡¡
¡ÊÊ¿»³Ìмù¡¢Medical Tribune¡á»þ»ö¡Ë2022/02/24 11:59
¿··¿¥³¥í¥Ê¥¦¥¤¥ë¥¹´¶À÷¾É¡ÊCOVID-19¡Ë¤Ø¤Î͸úÀ¤Ë¤Ä¤¤¤ÆµÄÏÀ¤¬Â³¤¤¤Æ¤¤¤ë¹³´óÀ¸ÃîÌô¥¤¥Ù¥ë¥á¥¯¥Á¥ó¤Ë¡¢¿·¤¿¤Ê¥é¥ó¥À¥à²½Èæ³Ó»î¸³¡ÊRCT¡Ë¤Î·ë²Ì¤¬¼¨¤µ¤ì¤¿¡£¥Þ¥ì¡¼¥·¥¢¡¦Raja Permaisuri Bainun Hospital¤ÎSteven Chee Loon Lim»á¤é¤ÏJAMA Intern Med¡Ê2022ǯ2·î18Æü¥ª¥ó¥é¥¤¥óÈǡˤǡ¢¹â¥ê¥¹¥¯¤ÎCOVID-19´µ¼Ô¤òÂоݤ˥¤¥Ù¥ë¥á¥¯¥Á¥ó¤Î͸úÀ¤ò¸¡Æ¤¤·¤¿¤È¤³¤í¡¢Æ±Ìô¤Ë½Å¾É²½¤òËɤ°¸ú²Ì¤Ïǧ¤á¤é¤ì¤Ê¤«¤Ã¤¿¤ÈÊó¹ð¤·¤¿¡£
- Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities The I-TECH Randomized Clinical Trial Steven Chee Loon Lim, Chee Peng Hor, Kim Heng Tay, et al., JAMA Intern Med. Published online February 18, 2022. doi:10.1001/jamainternmed.2022.0189
¥¤¥Ù¥ë¥á¥¯¥Á¥ó»ÈÍѤÎͳ²»ö¾Ý¤òÊó¹ð ¥Ñ¥ó¥Ç¥ß¥Ã¥¯¸å¡¢Êƹñ¤Ç»ÈÍÑÎ㤬µÞÁý¡¡
2021ǯ10·î22Æü 17:28, Medical Tribune
¡¡¹³´óÀ¸ÃîÌô¥¤¥Ù¥ë¥á¥¯¥Á¥ó¤Ë¿··¿¥³¥í¥Ê¥¦¥¤¥ë¥¹´¶À÷¾É¡ÊCOVID-19¡Ë¤ËÂФ¹¤ë¼£ÎŸú²Ì¤ò´üÂÔ¤¹¤ë¸þ¤¤¬¤¢¤ë¤â¤Î¤Î¡¢¥é¥ó¥À¥à²½Èæ³Ó»î¸³¡ÊRCT¡Ë¤Ç͸úÀ¤Ï¼¨¤µ¤ì¤Æ¤¤¤Ê¤¤¡£¤·¤«¤·¡¢Êƹñ¤Ç¤ÏCOVID-19¥Ñ¥ó¥Ç¥ß¥Ã¥¯¸å¤Ë½èÊý¤¬µÞÁý¤·¤Æ¤ª¤ê¡¢ÊƼÀÉÂÂкö¥»¥ó¥¿¡¼¡ÊCDC¡Ë¤¬¥¤¥Ù¥ë¥á¥¯¥Á¥ó¤Î»ÈÍѤËÃí°Õ¤ò´µ¯¤¹¤ë»öÂ֤ȤʤäƤ¤¤ë¡£ÊÆ¡¦Oregon Health and Science University¤ÎCourtney Temple»á¤é¤ÏNew Engl J Med¡Ê2021ǯ10·î21Æü¥ª¥ó¥é¥¤¥óÈǡˤǡ¢Æ±¹ñ¥ª¥ì¥´¥ó½£¤ÎÅÅÏÃÁêÃÌ¥»¥ó¥¿¡¼¤Ë´ó¤»¤é¤ì¤¿¥¤¥Ù¥ë¥á¥¯¥Á¥ó»ÈÍÑÎã¤Ë¤ª¤±¤ëͳ²»ö¾Ý¤Î»öÎã¤ò¾Ò²ð¡£21ÎãÃæ6Î㤬Æþ±¡¤·¤¿¤ÈÊó¹ð¤·¤¿¡£
- Toxic Effects from Ivermectin Use Associated with Prevention and Treatment of Covid-19¡¡Courtney Temple, Ruby Hoang, Robert G. Hendrickson¡¡N Engl J Med 2021; 385:2197-2198
High-dose ivermectin for early treatment of COVID-19 (COVER study): a randomised, double-blind, multicentre, phase II, dose-finding, proof-of-concept clinical trial
Dora Buonfrate, Fabio Chesini, Davide Martini, Maria Carla Roncaglioni, Maria Luisa Ojeda Fernandez, Maria Francesca Alvisi, Irene De Simone, Eliana Rulli, Alessandro Nobili, Giacomo Casalini, Spinello Antinori, Marco Gobbi, Caterina Campoli, Michela Deiana, Elena Pomari, Gianluigi Lunardi, Roberto Tessari , Zeno Bisoffi, Int J Antimicrob Agents. 2022 Feb;59(2):106516.
¥¤¥Ù¥ë¥á¥¯¥Á¥ó¤Ï¹âÍÑÎ̤Ǥâ°ÂÁ´¤À¤¬¡¢¥¦¥¤¥ë¥¹Î̤ò¸º¤é¤¹¸ú²Ì¤Ï¤Ê¤«¤Ã¤¿¡¢¤È¤¤¤¦·ëÏÀ¡£
Pharmacometrics of high dose ivermectin in early COVID-19: an open label, randomized, controlled adaptive platform trial (PLATCOV)¡¡
William HK Schilling et al., https://doi.org/10.7554/eLife.83201
¹âÍÑÎ̤Υ¤¥Ù¥ë¥á¥¯¥Á¥ó¤Ï¡¢COVID-19¤Î½é´ü¾É¾õ¤ËÂФ·¤Æ¡¢Â¬Äê²Äǽ¤Ê¹³¥¦¥¤¥ë¥¹³èÀ¤ò¼¨¤µ¤Ê¤«¤Ã¤¿¡£
¥Ë¥å¡¼¥¹
- ¡Ö²Ê³ØÅªº¬µò¡×¤Î±¢ËÅÏÀ¤Ë¥À¥Þ¤µ¤ì¤ë¤Ê¡ª¡¡ÉÍëΦÂÀ¡¢ÏÀºÂ¡¢2022ǯ04·î11Æü
- ¡Ö¥³¥í¥Ê¤Ë¸ú¤¯¡×´üÂÔ¤µ¤ì¤¿¤¢¤ÎÌô¤Ïº£¡¡·ÇºÜÏÀʸű²ó¤â¡¡ËèÆü¿·Ê¹ 2022/3/14 06:00¡ÊºÇ½ª¹¹¿· 3/15 20:01¡Ë
¡Ö¸í²ò¤ò¾·¤¯¸«½Ð¤·¤Î¥Ä¥¤¡¼¥È¤òºï½ü¤¹¤ë¡£À¤³¦ÊÝ·òµ¡´Ø¡ÊWHO¡Ë¤Ï»ÈÍѤˤĤ¤¤Æ·Ù¹ð¤·¤Æ¤¤¤ë¡×¡£¥í¥¤¥¿¡¼ÄÌ¿®¤Ï1·îËö¡¢¹³´óÀ¸ÃîÌô¡Ö¥¤¥Ù¥ë¥á¥¯¥Á¥ó¡×¤Ë´Ø¤¹¤ëȯ¿®¤òSNS¡Ê¥Í¥Ã¥È¸òή¥µ¡¼¥Ó¥¹¡Ë¾å¤ÇÄûÀµ¤·¤¿¡£
¡¡
¡¡È¯Ã¼¤Ï¡¢Ì¾¸Å²°»Ô¤ÎÀ½Ìô²ñ¼Ò¡Ö¶½Ï¡פ¬¸øÉ½¤·¤¿¡Ö¥¤¥Ù¥ë¥á¥¯¥Á¥ó¤Î¡Ø¥ª¥ß¥¯¥í¥ó³ô¡Ù¤Ø¤Î¹³¥¦¥¤¥ë¥¹¸ú²Ì¤ò³Îǧ¡×¤ÈÂꤷ¤¿¥×¥ì¥¹¥ê¥ê¡¼¥¹¤À¡£¤¢¤¯¤Þ¤Ç»î¸³´ÉÆâ¤ÎºÙ˦¼Â¸³¤Î·ë²Ì¤Ë¤¹¤®¤º¡¢¼ÂºÝ¤Ë´µ¼Ô¤ËÅêÍ¿¤·¤Æ¸¡¾Ú¤·¤¿Î×¾²»î¸³¤Î·ë²Ì¤Ç¤Ï¤Ê¤«¤Ã¤¿¤¬¡¢¥í¥¤¥¿¡¼¤¬Åê¹Æ¤·¤¿¡ÖÎ×¾²»î¸³¤Ç¥ª¥ß¥¯¥í¥ó³ô¤Ø¤Î͸úÀ¤ò³Îǧ¡×¤È¤Î¥Ä¥¤¡¼¥È¤Ï½Ö¤¯´Ö¤Ë³È»¶¤·¤¿¡£
- Texas doctor who promoted ivermectin as Covid treatment suspended by hospital¡¡Nov. 16, 2021, 2:19 AM JST / Updated Nov. 16, 2021, 2:25 AM JST, By Marlene Lenthang, nbcnews
- ¥¤¥Ù¥ë¥á¥¯¥Á¥ó¡¢ ¸í¤Ã¤¿²Ê³Ø¤¬À¸¤ó¤À¿··¿¥¦¥¤¥ë¥¹¡ÖÆÃ¸úÌô¡×¡¡2021ǯ10·î9Æü¡¢¥ì¥¤¥Á¥§¥ë¡¦¥·¥å¥ì¥¢¡¢¥¸¥ã¥Ã¥¯¡¦¥°¥Ã¥É¥Þ¥ó¡¢BBC¥ê¥¢¥ê¥Æ¥£¡¼¡¦¥Á¥§¥Ã¥¯¡Ê¥Õ¥¡¥¯¥È¥Á¥§¥Ã¥¯¡Ë¡¢BBC News
·×26·ï¤Î¸¦µæ¤Î¤¦¤Á5·ï¤Ç¤Ï¡¢¥Ç¡¼¥¿¤¬µ¶Â¤¤µ¤ì¤¿²ÄǽÀ¤¬¤¢¤Ã¤¿¡£Î㤨¤Ð¡¢»ö¼Â¾åÉÔ²Äǽ¤Ê¿ôÃͤ¬´Þ¤Þ¤ì¤Æ¤¤¤¿¤ê¡¢Æ±¤¸´µ¼Ô¤Î¥Ç¡¼¥¿¤¬Ê£¿ô²ó»ÈÍѤµ¤ì¤ë¤Ê¤É¤·¤Æ¤¤¤¿¡£
¡¡
¤µ¤é¤ËÊ̤Î5·ï¤Ç¤Ï¡¢¿ôÃͤΤĤ¸¤Ä¤Þ¤¬¹ç¤ï¤Ê¤«¤Ã¤¿¤ê¡¢¥Ñ¡¼¥»¥ó¥Æ¡¼¥¸¤Î»»½Ð¤Ë¸í¤ê¤¬¤¢¤Ã¤¿¤Û¤«¡¢Ãϰè¤Î°åÎŵ¡´Ø¤¬¼£¸³¤Î¼Â»Ü¤òǧ¼±¤·¤Æ¤¤¤Ê¤¤¤Ê¤É¡¢½ÅÂç¤ÊÌäÂ꤬¸«¤Ä¤«¤Ã¤¿¡£
¡¡
¤³¤¦¤·¤¿¼£¸³¤ÎÉÔÈ÷¤Ë²Ã¤¨¡¢¤³¤ì¤é¤Î¸¦µæ¤ÎÃø¼Ô14¿Í¤ÏÆÈΩĴºº¥Á¡¼¥à¤Ë¥Ç¡¼¥¿¤òÊÖÁ÷¤·¤Ê¤«¤Ã¤¿¡£¤³¤Î¤³¤È¤«¤é¡¢Ä´ºº¥Á¡¼¥à¤Î²Ê³Ø¼Ô¤¿¤Á¤Ï¡¢ÉÔÀµ¹Ô°Ù¤¬¤¢¤Ã¤¿²ÄǽÀ¤¬¤¢¤ë¤È»ØÅ¦¤·¤Æ¤¤¤ë¡£
¡¡
Ä´ºº¥Á¡¼¥à¤¬Ä´¤Ù¤¿¸¦µæÏÀʸ¤Î¥µ¥ó¥×¥ë¤Ë¤Ï¡¢À¤³¦³Æ¹ñ¤Î¼Á¤Î¹â¤¤¸¦µæ¤â´Þ¤Þ¤ì¤Æ¤¤¤¿¡£¤·¤«¤·Â礤ÊÌäÂê¤Ï¡¢¥¤¥Ù¥ë¥á¥¯¥Á¥ó¤Î¸ú²Ì¤òÂ礤¯¤¦¤¿¤¦¸¦µæ¤Ë¤¢¤Ã¤¿¡£¼ÂºÝ¡¢¥¤¥Ù¥ë¥á¥¯¥Á¥ó¤Çµß¤ï¤ì¤¿¤È¤µ¤ì¤ëÌ¿¤ä´¶À÷¤Î¿ô¤¬Â礤¤¤Û¤É¡¢ÙÔ¤¤ä¸¦µæ·ë²Ì¤¬Ìµ¸ú¤Ê¤Î¤Ç¤Ï¤Ê¤¤¤«¤È¤¤¤¦·üǰ¤¬Â礤¤¤³¤È¤¬¤ï¤«¤Ã¤¿¤È¤·¤Æ¤¤¤ë¡£
- ¥¤¥Ù¥ë¥á¥¯¥Á¥óÏÀʸ¤ÏÙÔ¤¡© ¥×¥ì¥×¥ê¥ó¥È¤Î°Ç¡¡2021/07/19¡¢ÁÒ¸¶Í¥¡Ê¶áµ¦Ãæ±û¸ÆµÛ´ï¥»¥ó¥¿¡¼¡Ë¡¢Æü·Ð¥á¥Ç¥£¥«¥ë
¤³¤³¤ÇÌäÂê¤Ë¤µ¤ì¤Æ¤¤¤ë¤Î¤Ï°Ê²¼¤Î¥×¥ì¥×¥ê¥ó¥È¡£¤½¤â¤½¤âººÆÉ¤ò¤Þ¤ÀÄ̤äƤ¤¤Ê¤¤¥×¥ì¥×¥ê¥ó¥È¡ÊÏÀʸ¤Ë¤Ê¤ëÁ°¤ÎÃʳ¬¡Ë¤òº¬µò¤È¤·¤Æ°úÍѤ¹¤ë¤³¤È¤ËÂ礤ÊÌäÂ꤬¤¢¤ë¡£
- Efficacy and safety of Ivermectin for treatment and prophylaxis of COVID-19 pandemic¡¡Elgazzar, A, et al. ¡¢Research Square, 100956
Research Square¤Ë¤è¤ë¤È¡¢·üǰ¤¬É½ÌÀ¤µ¤ì¤¿¤³¤È¤Ë¤è¤ê2021ǯ7·î14Æü¤Ë¤³¤Î¥×¥ì¥×¥ê¥ó¥È¤Ïű²ó¤µ¤ì¤Æ¤ª¤ê¡¢2021ǯ7·î19Æü¸½ºßÀµ¼°¤ËÄ´ººÃæ¤È¤Î¤³¤È¡£Jack Lawrence¤È¤¤¤¦¿Íʪ¤¬¤³¤ÎÏÀʸ¤ÎÌäÂêÅÀ¤ò»ØÅ¦¤·¤Æ¤ª¤ê¡¢Èà¤Î¶¨ÎϼÔNick Brown»á¤¬°Ê²¼¤Î¥Ö¥í¥°¤Ë¤½¤ÎÅ¿Ëö¤ò¤Þ¤È¤á¤Æ¤¤¤ë¡£
- Some problems in the dataset of a large study of Ivermectin for the treatment of Covid-19¡¡15 July 2021¡¢Nick Brown's blog
- Flawed ivermectin preprint highlights challenges of COVID drug studies¡¡02 August 2021¡¢Nature
¤³¤Á¤é¤âElgazzar¤é¤Î¥×¥ì¥×¥ê¥ó¥È¤Ë´Ø¤¹¤ëµ»ö¡£
- Bad MATH+? Covid treatment paper by Pierre Kory retracted for flawed results¡¡Retraction Watch¡¢November 9, 2021¡¢AuthorAdam Marcus
- Ivermectin-COVID-19 study retracted; authors blame file mixup¡¡November 2, 2021¡¢Author¡§Adam Marcus¡¢Retraction Watch
- ¶îÃîÌô¡Ö¥¤¥Ù¥ë¥á¥¯¥Á¥ó¡×¡¢ÊƤǥ³¥í¥Ê¼£ÎÅÌÜŪ¤Î»ÈÍѤ˷پ⡡2021ǯ9·î5Æü¡¢¹¹¿· 2021ǯ9·î7Æü¡¢BBC News
- COVID-19¤ËÇÏÍѤÎÌô¡Ä¡Ä¥¤¥Ù¥ë¥á¥¯¥Á¥ó¤ò¤á¤°¤ëµÄÏÀ¤ò²òÀâ¡¡2021ǯ9·î24Æü¡¢BBC News
- Why You Should Not Use Ivermectin to Treat or Prevent COVID-19¡¡Food and Drug Administration¡¢¥¢¥á¥ê¥«FDA¤«¤é¤Î·Ù¹ð¡£
- ¡Ö¤ªÁ°¤â¥¤¥Ù¥ë¥á¥¯¥Á¥ó°û¤á¡ª¡×¸Ä¿ÍÍ¢Æþ¤·¤¿Ìô¤òÇÛ¤ë¾å»Ê¡¢°å¼Ô¤Ç¤â¤Ê¤¤¤Î¤ËÂç¾æÉס©¡¡10/29(¶â) 9:55ÇÛ¿®¡¢ÊÛ¸î»Î¥É¥Ã¥È¥³¥à¥Ë¥å¡¼¥¹
ÊÛ¸î»Î¥É¥Ã¥È¥³¥à¤Ê¤Î¤Ç¡¢Ë¡Î§¾å¤ÎÏäΤߡ£
¡Ö¸Ä¿ÍÍ¢Æþ¤ò¤·¤¿¥¤¥Ù¥ë¥á¥¯¥Á¥ó¤ò¼þ°Ï¤ËÇۤ뤳¤È¤ÏÌôµ¡Ë¡¤Ç¶Ø»ß¤µ¤ì¤Æ¤¤¤Þ¤¹¡£¤â¤È¤â¤È¼«Ê¬¼«¿È¤Ç»ÈÍѤ¹¤ë¾ì¹ç¤Ë¸Â¤Ã¤ÆÌ¤¾µÇ§°åÌôÉʤò¸Ä¿ÍÍ¢Æþ¤¹¤ë¤³¤È¤¬¤Ç¤¤ëÍýͳ¤Ï¡¢³°¹ñ¤Ç¼õ¤±¤¿Ìôʪ¼£ÎŤò·Ñ³¤·¤¿¤ê¡¢³¤³°¤«¤é¤Îι¹Ô¼Ô¤¬¾ïÈ÷Ìô¤È¤·¤Æ·È¹Ô¤¹¤ë¾ì¹ç¤Ø¤ÎÇÛθ¤Ë¤¢¤ê¤Þ¤¹¡£¤½¤Î¤¿¤á¡¢¸Ä¿ÍÍ¢Æþ¤·¤¿¥¤¥Ù¥ë¥á¥¯¥Á¥ó¤òÇÛ¤ë¤è¤¦¤Ê¤³¤È¤ÏÀäÂФˤ·¤Ê¤¤¤è¤¦¤Ë¤·¤Þ¤·¤ç¤¦¡×
¡Ö̤¾µÇ§°åÌôÉʤˤĤ¤¤ÆÍ¢ÆþÂå¹Ô¶È¼Ô¤òÍøÍѤ¹¤ë¤³¤È¼«ÂΤ¬Ä¾¤Á¤ËÌäÂê¤Ë¤Ï¤Ê¤ê¤Þ¤»¤ó¤¬¡¢Í¢ÆþÂå¹Ô¶È¼Ô¤ÎÃæ¤Ë¤ÏÌôµ¡Ë¡¤Ë°ãÈ¿¤·¤¿·Á¤Ç±Ä¶È¤ò¤ª¤³¤Ê¤¦°¼Á¤Ê»ö¶È¼Ô¤â¸ºß¤·¤Þ¤¹¡£¤½¤Î¤è¤¦¤Ê»ö¶È¼Ô¤ËÍ¢ÆþÂå¹Ô¶È̳¤ò°ÑÂ÷¤·¤¿¾ì¹ç¡¢¥È¥é¥Ö¥ë¤Ë´¬¤¹þ¤Þ¤ì¤ë²ÄǽÀ¤Ï¤¢¤ê¤Þ¤¹¡£
¡¡
°ãË¡¤Ê̤¾µÇ§°åÌôÉʤÎÍ¢ÆþÂå¹Ô¶È¤È¤·¤Æ¤Ï¡¢¹¹ð¤Ë¤è¤Ã¤ÆÉÔÆÃÄê¿¿ô¤Î¼Ô¤Î´õ˾¤òÊç¤Ã¤¿¤ê¡¢Êç¤Ã¤¿¾å¤Ç¾¦ÉʤȤʤë̤¾µÇ§°åÌôÉʤò°ì³çȯÁ÷¤Ë¤è¤Ã¤Æ»ö¶È¼Ô¤¬Ä¾ÀÜÍ¢Æþ¤ò¼õ¤±¡¢¸Ä¿Í¤ËÂФ·¤Æ¾¦ÉʤòȯÁ÷¡ÊÈÎÇä¡Ë¤¹¤ë¤è¤¦¤Ê¤â¤Î¤¬¤¢¤ê¤Þ¤¹¡£Ì¤¾µÇ§°åÌôÉʤˤĤ¤¤Æ¤ÏÈó¾ï¤Ë¸·¤·¤¤Ìôµ¡Ë¡¾å¤Î¹¹ðµ¬À©¤¬¤¢¤ê¤Þ¤¹¤Î¤Ç¡¢¿··¿¥³¥í¥ÊÂкö¤Ç¥¤¥Ù¥ë¥á¥¯¥Á¥ó¤ÎÍ¢Æþ¤òÊç¤ë¤è¤¦¤Ê¹¹ð¤Ï¤ä¤Ã¤Æ¤Ï¤¤¤±¤Ê¤¤¤â¤Î¤È¤ª¹Í¤¨²¼¤µ¤¤¡£
¡¡
¤Þ¤¿¡¢¾¦ÉʤÎȯÁ÷¤òľÀܳ°¹ñ¤Î»ö¶È¼Ô¤«¤é¸Ä¿Í¤ËÂФ·¤Æ¼è¼¡¤ò¤»¤º¡¢°ìö»ö¶È¼Ô¤¬Í¢Æþ¤ò¤·¤¿¸å¤Ë¸Ä¿Í¤ØÈ¯Á÷¤ò¤·¤Æ¤·¤Þ¤¦¤È¡¢Í¢Æþ¤ÎÂå¹Ô¤Ç¤Ï¤Ê¤¯Ì¤¾µÇ§°åÌôÉʤÎÈÎÇä¹Ô°Ù¤ÈȽÃǤµ¤ì¤ë¤¿¤á¡¢¤³¤ì¤â¤ä¤Ã¤Æ¤Ï¤¤¤±¤Ê¤¤¤â¤Î¤È¤ª¹Í¤¨²¼¤µ¤¤¡Ê¤¢¤¯¤Þ¤ÇÍ¢ÆþÂå¹Ô»ö¶È¼Ô¤¬¤Ç¤¤ë¤Î¤ÏÍ¢Æþ¤Î¡ÖÂå¹Ô¡×¤Ç¤¹¡Ë¡×
- ¥¤¥Ù¥ë¥á¥¯¥Á¥ó¤ÎÇä¤ê¾å¤²¤¬ÊƤÇ24Çܤˡ¢¥³¥í¥Ê¼£ÎŤΤĤâ¤ê¤¬µßµÞ¼£Îż¼¤¬ËþÇդˡ¡2021ǯ9·î3Æü¡Ê¶â¡Ë16»þ50ʬ¡¢¥¸¥ç¥ó¡¦¥¸¥ã¥¯¥½¥ó¡¢NewsWeek
ÆüËܰʾå¤ËÈ¿¥ï¥¯¥Á¥óÀªÎϤζ¯¤¤¥¢¥á¥ê¥«¤Ç¤Ï¥¤¥Ù¥ë¥á¥¯¥Á¥ó¤¬Âç¿Íµ¤¤È¤Ê¤ê¡¢¤¹¤´¤¤¤³¤È¤Ë¤Ê¤Ã¤Æ¤¤¤ëÍͻҡ£
ÊÆ¥ª¥¯¥é¥Û¥Þ½£¹Ù³°¤Î¤¢¤ë°å»Õ¤Ë¤è¤ì¤Ð¡¢ÇÏÍѤδóÀ¸Ãî¶î½üÌô¤Ë»È¤ï¤ì¤ë¥¤¥Ù¥ë¥á¥¯¥Á¥ó¤ò¿··¿¥³¥í¥Ê¥¦¥¤¥ë¥¹´¶À÷¾É¤Î¼£ÎÅÌô¤È¤·¤Æ²á¾êÀݼ褷¤¿¿Í¡¹¤¬¡¢Ãϸµ¤Îɱ¡¤ÎµßµÞ½èÃÖ¼¼¤òËä¤á¿Ô¤¯¤·¤Æ¤¤¤ë¤È¤¤¤¦¡£
¡¡
Ʊ½£ÅìÉô¤ÈÆîÉô¤ÎÊ£¿ô¤ÎµßµÞ½èÃÖ¼¼¤Ë¶Ð̳¤·¤Æ¤¤¤ë¥¸¥§¥¤¥½¥ó¡¦¥Þ¥¯¥¨¥ê¥¨°å»Õ¤Ï¡¢Ãϸµ¥Æ¥ì¥Ó¶ÉKFOR-TV¤ËÂФ·¤Æ¡¢¡Ö¤³¤ÎÌô¤ÎÉþÍѤˤ¢¤¿¤Ã¤Æ°å»Õ¤Î½èÊý¤¬É¬ÍפʤΤˤÏÍýͳ¤¬¤¢¤ë¡£¾ì¹ç¤Ë¤è¤Ã¤Æ¤Ï´í¸±¤À¤«¤é¤À¡×¤È½Ò¤Ù¤¿¡£
ÊÆ¼ÀÉÂÂкö¥»¥ó¥¿¡¼¡ÊCDC¡Ë¤ÏºÇ¶á¤ÎÀ¼ÌÀ¤Ç¡¢¡ÖÌô¶É¤ä¾®ÇäŹ¤Ç¥¤¥Ù¥ë¥á¥¯¥Á¥ó¤Î¼è¤ê°·¤¤Î̤¬Áý¤¨¤Æ¤¤¤ë¤¬¡¢¿Í´ÖÍѤËÈÎÇ䤵¤ì¤Æ¤¤¤ë¤â¤Î¤Ç¤Ï¤Ê¤¤¡×¤ÈÀâÌÀ¤·¤¿¡£
¡¡
CDC¤ÏÀ¼ÌÀ¤ÎÃæ¤Ç¤µ¤é¤Ë¡¢¡ÖFDA¤Ï¿··¿¥³¥í¥Ê´¶À÷¾É¤ÎͽËÉÌô¤Þ¤¿¤Ï¼£ÎÅÌô¤È¤·¤Æ¡¢¥¤¥Ù¥ë¥á¥¯¥Á¥ó¤Î»ÈÍѤòǧ²Ä¤â¾µÇ§¤â¤·¤Æ¤¤¤Ê¤¤¡×¤È½Ò¤Ù¤¿¡£¡ÖÊÆ¹ñΩ±ÒÀ¸¸¦µæ½ê¡ÊNIH¡Ë¤Î¿··¿¥³¥í¥Ê´¶À÷¾É¼£ÎÅ¥¬¥¤¥É¥é¥¤¥ó°Ñ°÷²ñ¤â¡¢¸½Ãʳ¬¤Ç¡¢¿··¿¥³¥í¥Ê´¶À÷¾É¤Î¼£ÎÅÌô¤È¤·¤Æ¥¤¥Ù¥ë¥á¥¯¥Á¥ó¤ò¿ä¾©¤¹¤ë½½Ê¬¤Ê¥Ç¡¼¥¿¤Ï¤Ê¤¤¤ÈȽÃǤ·¤Æ¤¤¤ë¡×
ÊÆ¹ñ°å»Õ²ñ¡ÊAMA¡Ë¡¢Á´ÊÆÌôºÞ»Õ¶¨²ñ¡ÊAPhA¡Ë¤ÈÁ´ÊÆÌôºÞ»Õ·ò¹¯¶¨²ñ¡ÊASHP¡Ë¤Ï¡¢9·î1Æü¤Ë¶¦Æ±¤ÇÀ¼ÌÀ¤òȯɽ¤·¤¿¡£
¡¡
¡Ö¥¤¥Ù¥ë¥á¥¯¥Á¥ó¤Î½èÊý¡¦ÈÎÇäÎ̤¬¥Ñ¥ó¥Ç¥ß¥Ã¥¯Á°¤ËÈæ¤Ù¤Æ24ÇܤËÁý¤¨¤Æ¤ª¤ê¡¢²áµî¿ô¥«·î¤ÇµÞÁý¤·¤Æ¤¤¤ë¤È¤¤¤¦ÊóÆ»¤Ë¡¢´íµ¡´¶¤òÊç¤é¤»¤Æ¤¤¤ë¡×¡Ö²æ¡¹¤È¤·¤Æ¤Ï¡¢Î×¾²»î¸³°Ê³°¤Ç¡¢¿··¿¥³¥í¥Ê´¶À÷¾É¤ÎͽËɤª¤è¤Ó¼£ÎÅÌô¤È¤·¤Æ¥¤¥Ù¥ë¥á¥¯¥Á¥ó¤ò½èÊý¡¢ÈÎÇ䤪¤è¤Ó»ÈÍѤ¹¤ë¤³¤È¤ò¡¢Â¨ºÂ¤Ë¤ä¤á¤ë¤è¤¦µá¤á¤ë¡×
¡¡
FDA¤Ï¤³¤ÎÌäÂê¤Ë¤Ä¤¤¤Æ¡¢¿Æ¤·¤ß¤ä¤¹¤¤¥á¥Ã¥»¡¼¥¸¤òȯ¿®¤·¤è¤¦¤È¡¢8·î¤Ë¥Ä¥¤¥Ã¥¿¡¼¤Ë¼¡¤Î¤è¤¦¤ËÅê¹Æ¤·¤¿¡£¡Ö¤¢¤Ê¤¿¤ÏÇϤǤϤ¢¤ê¤Þ¤»¤ó¡£µí¤Ç¤â¤¢¤ê¤Þ¤»¤ó¡£¤³¤ì¤Ï¿¿ÌÌÌܤÊÏäǤ¹¡£¤ä¤á¤Æ¤¯¤À¤µ¤¤¡×
ÅÄÊ¥ÀµÊ¸»á
- °Ý¿·¸õÊ䤬¿··¿¥³¥í¥Ê´¶À÷¡¢Åìµþ¡¡¡Ö»ö̳½êÆâ¤Ë¥¯¥é¥¹¥¿¡¼¡×¡¡2021/10/28 - ¶¦Æ±ÄÌ¿®
½°±¡ÁªÅìµþ5¶è¤ËÆüËܰݿ·¤Î²ñ¤«¤éΩ¸õÊ䤷¤Æ¤¤¤ë°å»Õ¤ÎÅÄÊ¥ÀµÊ¸»á¡Ê63¡Ë¤Ï28Æü¡¢¿··¿¥³¥í¥Ê¤Ë´¶À÷¤·¤¿¤³¤È¤ò¼«¿È¤Î¥Õ¥§¥¤¥¹¥Ö¥Ã¥¯¤ÇÌÀ¤é¤«¤Ë¤·¤¿¡£¸ø¼¨¸å¤Ë¸õÊä¼Ô¤Î´¶À÷¤¬È½ÌÀ¤·¤¿¤Î¤Ï½é¤á¤Æ¤È¤ß¤é¤ì¤ë¡£¸½ºß¤ÏÆþ±¡Ãæ¤È¤¤¤¤¡¢¼èºà¤Ë¥á¡¼¥ë¤Ç¡Ö»ö̳½êÆâ¡Ê¤Î¥¹¥¿¥Ã¥Õ¡Ë¤Ë5¡¢6¿Í¤Î¥¯¥é¥¹¥¿¡¼¡Ê´¶À÷¼Ô½¸Ãġˤ¬È¯À¸¤·¤¿¡×¤È²óÅú¤·¤¿¡£
- ¸ÞËÜÌÚ¥¯¥ê¥Ë¥Ã¥¯±¡Ä¹@kuwamitsuosamu¥Ö¥í¥°¡¡¥¤¥Ù¥ë¥á¥¯¥Á¥ó¤ò½èÊý¤·¤Þ¤¯¤ë¤ª°å¼Ô¤µ¤ó¤¬½°µÄ±¡Áªµó¤ËΩ¸õÊä¡¡Åê¹ÆÆü2021-10-21¡¢¸ÞËÜÌÚ¥¯¥ê¥Ë¥Ã¥¯¡¢±¡Ä¹¥Ö¥í¥°
¡Ö¥¤¥Ù¥ë¥á¥¯¥Á¥ó+¥«¥â¥¹¥¿¥Ã¥È+¥¯¥é¥ê¥¹¥í¥Þ¥¤¥·¥ó»°¼ïÇÛ¹çºÞ¡×¤È¤¤¤¦¤â¤Î¤¬¿··¿¥³¥í¥Ê¤ÎÆÃ¸úÌô¤Ë¤Ê¤ë¤È¼çÄ¥¤¹¤ëÅÄÊ¥ÀµÊ¸¤Ê¤ë¿Íʪ¤¬°Ý¿·¤«¤éΩ¸õÊ䤷¡¢¤½¤Îľ¸å¡¢Áªµó»ö̳½êÆâ¤Ç¿··¿¥³¥í¥Ê¤Î¥¯¥é¥¹¥¿¡¼¤¬È¯À¸¤·¤¿¤È¤¤¤¦Ïá£